Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Arcturus Therapeutics Holdings Inc
ARCTCurrent price
18.69 USD
+0.05 USD (+0.27%)
Last closed
18.82 USD
Company
arcturusrx.com
ISIN
US03969T1097
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
570 590 400 USD
Yield for 12 month
-39.71 %
1Y
3Y
5Y
10Y
15Y
ARCT
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Address: 10628 Science Center Drive, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
69.11 USDP/E ratio
–Dividend Yield
–Current Year
+157 748 000 USD
Last Year
+205 755 000 USD
Current Quarter
+45 976 000 USD
Last Quarter
+32 598 000 USD
Current Year
+154 791 000 USD
Last Year
+62 704 000 USD
Current Quarter
+45 076 000 USD
Last Quarter
+38 012 000 USD
Key Figures ARCT
1 year
3 years
5 years
10 years
EBITDA
-85 669 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-13.6 %
PEG Ratio
–
Return On Equity TTM
-26.47 %
Wall Street Target Price
69.11 USD
Revenue TTM
163 866 000 USD
Book Value
9.56 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
374 %
Dividend Yield
–
Gross Profit TTM
62 948 000 USD
Earnings per share
-2.69 USD
Diluted Eps TTM
-2.69 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-43.92 %
Dividend Analytics ARCT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ARCT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:7
Payout Ratio
–
Last Split Date
16.11.2017
Dividend Date
16.11.2017
Stock Valuation ARCT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
2.4777
Enterprise Value Revenue
2.3203
Price Sales TTM
3.4821
Enterprise Value EBITDA
-25.6651
Price Book MRQ
2.2066
Financials ARCT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ARCT
For 52 weeks
17.52 USD
45 USD
50 Day MA
22.24 USD
Shares Short Prior Month
5 356 611
200 Day MA
29.35 USD
Short Ratio
13.05
Shares Short
5 455 552
Short Percent
31.66 %
BeatStart